Seattle Genetics (SGEN) ADCETRIS Gets FDA Approval

  • 0
  • 0

Seattle Genetics Incorporated - symbol SGEN - reported that the U.S. FDA has granted accelerated approval of ADCETRIS. ADCETRIS is the first approved by the FDA for Hodgkin lymphoma in more than 30 years, and provides a new therapeutic alternative for Hodgkin lymphoma and systemic anaplastic large cell lymphoma in these settings.

20 Aug 2011

72 Visualizações

adcetris, nasdaqsgen, sgen

Estatísticas do vídeo



Vídeos em Destaque